Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia

Not yet recruitingOBSERVATIONAL

Enrollment

2,883

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 31, 2032

Study Completion Date

July 31, 2032

Conditions

Breast Cancer

Interventions

DRUG

Ribociclib

CDK4/6 inhibitor

DRUG

Letrozole

Aromatase inhibitor

DRUG

Anastrozole

Aromatase inhibitor